KUNOVSKÝ, Lumír, Pavla TESARIKOVA, Zdeněk KALA, Radek KROUPA, Petr KYSELA, Jiří DOLINA and Jan TRNA. The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer. Canadian Journal of Gastroenterology and Hepatology. New York: Hindawi Publishing Corporation, 2018, vol. 2018, No 5389820, p. 1-10. ISSN 2291-2797.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer
Authors KUNOVSKÝ, Lumír (203 Czech Republic, belonging to the institution), Pavla TESARIKOVA (203 Czech Republic), Zdeněk KALA (203 Czech Republic, belonging to the institution), Radek KROUPA (203 Czech Republic, belonging to the institution), Petr KYSELA (203 Czech Republic, belonging to the institution), Jiří DOLINA (203 Czech Republic, belonging to the institution) and Jan TRNA (203 Czech Republic, guarantor, belonging to the institution).
Edition Canadian Journal of Gastroenterology and Hepatology, New York, Hindawi Publishing Corporation, 2018, 2291-2797.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30219 Gastroenterology and hepatology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.714
RIV identification code RIV/00216224:14110/18:00103475
Organization unit Faculty of Medicine
UT WoS 000442877300001
Keywords in English Pancreatic ductal adenocarcinoma
Tags 14110213, 14110223, EL OK, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 2/5/2019 13:46.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies with increasing incidence. The poor prognosis is due to the aggressive nature of the tumor, late detection, and the resistance to chemotherapy and radiotherapy. A radical surgery procedure is the only treatment that has been shown to improve the 5-year survival rate to 20-25%. However, the majority of patients (80-85%) are diagnosed with locally advanced or metastatic disease and just 15-20% patients are diagnosed in an early stage allowing them to undergo the potentially curative surgical resection. The early detection of PDAC without the use of invasive methods is challenging and discovery of a cost-effective biomarker with high specificity and sensitivity could significantly improve the treatment and survival in these patients. In this review, we summarize current and newly examined biomarkers in early PDAC detection.
PrintDisplayed: 25/4/2024 13:04